Literature DB >> 25122792

Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations.

Maria Lisa Knudsen1, Karl Ljungberg2, Maria Kakoulidou2, Linda Kostic2, David Hallengärd2, Juan García-Arriaza3, Andres Merits4, Mariano Esteban3, Peter Liljeström2.   

Abstract

UNLABELLED: Alphavirus replicons are potent inducers of CD8(+) T cell responses and thus constitute an attractive vaccine vector platform for developing novel vaccines. However, the kinetics and memory phenotype of CD8(+) T cell responses induced by alphavirus replicons are not well characterized. Furthermore, little is known how priming with alphavirus replicons affects booster immune responses induced by other vaccine modalities. We demonstrate here that a single immunization with an alphavirus replicon, administered as viral particles or naked DNA, induced an antigen-specific CD8(+) T cell response that had a sharp peak, followed by a rapid contraction. Administering a homologous boost before contraction had occurred did not further increase the response. In contrast, boosting after contraction when CD8(+) T cells had obtained a memory phenotype (based on CD127/CD62L expression), resulted in maintenance of CD8(+) T cells with a high recall capacity (based on CD27/CD43 expression). Increasing the dose of replicon particles promoted T effector memory (Tem) and inhibited T central memory development. Moreover, infection with a replicating alphavirus induced a similar distribution of CD8(+) T cells as the replicon vector. Lastly, the distribution of T cell subpopulations induced by a DNA-launched alphavirus replicon could be altered by heterologous boosts. For instance, boosting with a poxvirus vector (MVA) favored expansion of the Tem compartment. In summary, we have characterized the antigen-specific CD8(+) T cell response induced by alphavirus replicon vectors and demonstrated how it can be altered by homologous and heterologous boost immunizations. IMPORTANCE: Alphavirus replicons are promising vaccine candidates against a number of diseases and are by themselves developed as vaccines against, for example, Chikungunya virus infection. Replicons are also considered to be used for priming, followed by booster immunization using different vaccine modalities. In order to rationally design prime-boost immunization schedules with these vectors, characterization of the magnitude and phenotype of CD8(+) T cell responses induced by alphavirus replicons is needed. Here, we demonstrate how factors such as timing and dose affect the phenotypes of memory T cell populations induced by immunization with alphavirus replicons. These findings are important for designing future clinical trials with alphaviruses, since they can be used to tailor vaccination regimens in order to induce a CD8(+) T cell response that is optimal for control and/or clearance of a specific pathogen.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25122792      PMCID: PMC4248943          DOI: 10.1128/JVI.02223-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon.

Authors:  Agnes Le Bon; Nathalie Etchart; Cornelia Rossmann; Miranda Ashton; Sam Hou; Dirk Gewert; Persephone Borrow; David F Tough
Journal:  Nat Immunol       Date:  2003-09-21       Impact factor: 25.606

2.  Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.

Authors:  Maria L Knudsen; Alice Mbewe-Mvula; Maximillian Rosario; Daniel X Johansson; Maria Kakoulidou; Anne Bridgeman; Arturo Reyes-Sandoval; Alfredo Nicosia; Karl Ljungberg; Tomás Hanke; Peter Liljeström
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 3.  Innate recognition of viruses.

Authors:  Andreas Pichlmair; Caetano Reis e Sousa
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

4.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.

Authors:  J Schneider; S C Gilbert; T J Blanchard; T Hanke; K J Robson; C M Hannan; M Becker; R Sinden; G L Smith; A V Hill
Journal:  Nat Med       Date:  1998-04       Impact factor: 53.440

5.  Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming.

Authors:  Agnes Le Bon; Vanessa Durand; Elisabeth Kamphuis; Clare Thompson; Silvia Bulfone-Paus; Cornelia Rossmann; Ulrich Kalinke; David F Tough
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

6.  Programming for CD8 T cell memory development requires IL-12 or type I IFN.

Authors:  Zhengguo Xiao; Kerry A Casey; Stephen C Jameson; Julie M Curtsinger; Matthew F Mescher
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates.

Authors:  Hilario J Ramos; Ann M Davis; Alexander G Cole; John D Schatzle; James Forman; J David Farrar
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

8.  Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response.

Authors:  Kim Blom; Monika Braun; Martin A Ivarsson; Veronica D Gonzalez; Karolin Falconer; Markus Moll; Hans-Gustaf Ljunggren; Jakob Michaëlsson; Johan K Sandberg
Journal:  J Immunol       Date:  2013-01-21       Impact factor: 5.422

9.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

10.  Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein.

Authors:  M D Ryan; J Drew
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more
  15 in total

1.  Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.

Authors:  María Q Marín; Patricia Pérez; Karl Ljungberg; Carlos Óscar S Sorzano; Carmen E Gómez; Peter Liljeström; Mariano Esteban; Juan García-Arriaza
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

2.  Chikungunya Virus Evades Antiviral CD8+ T Cell Responses To Establish Persistent Infection in Joint-Associated Tissues.

Authors:  Bennett J Davenport; Christopher Bullock; Mary K McCarthy; David W Hawman; Kenneth M Murphy; Ross M Kedl; Michael S Diamond; Thomas E Morrison
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

3.  Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.

Authors:  Mariane Melo; Ely Porter; Yuan Zhang; Murillo Silva; Na Li; Brian Dobosh; Alessia Liguori; Pat Skog; Elise Landais; Sergey Menis; Devin Sok; David Nemazee; William R Schief; Ron Weiss; Darrell J Irvine
Journal:  Mol Ther       Date:  2019-08-19       Impact factor: 11.454

4.  Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.

Authors:  Pierre Roques; Karl Ljungberg; Beate M Kümmerer; Leslie Gosse; Nathalie Dereuddre-Bosquet; Nicolas Tchitchek; David Hallengärd; Juan García-Arriaza; Andreas Meinke; Mariano Esteban; Andres Merits; Roger Le Grand; Peter Liljeström
Journal:  JCI Insight       Date:  2017-03-23

5.  A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.

Authors:  Jesse H Erasmus; Amit P Khandhar; Jeff Guderian; Brian Granger; Jacob Archer; Michelle Archer; Emily Gage; Jasmine Fuerte-Stone; Elise Larson; Susan Lin; Ryan Kramer; Rhea N Coler; Christopher B Fox; Dan T Stinchcomb; Steven G Reed; Neal Van Hoeven
Journal:  Mol Ther       Date:  2018-08-02       Impact factor: 11.454

6.  Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.

Authors:  Maria L Knudsen; Karl Ljungberg; Roger Tatoud; Jonathan Weber; Mariano Esteban; Peter Liljeström
Journal:  PLoS One       Date:  2015-02-02       Impact factor: 3.240

7.  A Dual-Color Bioluminescence Reporter Mouse for Simultaneous in vivo Imaging of T Cell Localization and Function.

Authors:  Jan Willem Kleinovink; Laura Mezzanotte; Giorgia Zambito; Marieke F Fransen; Luis J Cruz; J Sjef Verbeek; Alan Chan; Ferry Ossendorp; Clemens Löwik
Journal:  Front Immunol       Date:  2019-01-08       Impact factor: 7.561

8.  Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination.

Authors:  Yanqin Ren; Na Wang; Weiguo Hu; Xiaoyan Zhang; Jianqing Xu; Yanmin Wan
Journal:  Sci Rep       Date:  2015-12-15       Impact factor: 4.379

9.  HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.

Authors:  J Hinkula; S Petkov; K Ljungberg; D Hallengärd; A Bråve; M Isaguliants; T Falkeborn; S Sharma; V Liakina; M Robb; M Eller; B Moss; G Biberfeld; E Sandström; C Nilsson; K Markland; P Blomberg; B Wahren
Journal:  Heliyon       Date:  2017-06-29

10.  Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens.

Authors:  Stephanie van de Wall; Karl Ljungberg; Peng Peng Ip; Annemarie Boerma; Maria L Knudsen; Hans W Nijman; Peter Liljeström; Toos Daemen
Journal:  Oncoimmunology       Date:  2018-07-26       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.